Safety and clinical activity of durvalumab (MEDI4736), an anti-PD-L1 antibody, in treatment-naive patients with advanced non small-cell lung cancer Meeting Abstract
| Authors: | Antonia, S. J.; Kim, S. W.; Spira, A. I.; Ahn, M. J.; Ou, S. H. I.; Stjepanovic, N.; Fasolo, A.; Jager, D.; Ott, P. A.; Wainberg, Z. A.; Wakelee, H. A.; Goldman, J. W.; Kurland, J.; Rebelatto, M. C.; Yao, W.; Gupta, A. K.; Blake-Haskins, J. A.; Segal, N. H. |
| Abstract Title: | Safety and clinical activity of durvalumab (MEDI4736), an anti-PD-L1 antibody, in treatment-naive patients with advanced non small-cell lung cancer |
| Meeting Title: | 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 34 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2016 Jun 3-7 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2016-05-20 |
| Start Page: | 463s |
| Language: | English |
| ACCESSION: | WOS:000404711506177 |
| DOI: | 10.1200/JCO.2016.34.15_suppl.9029 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 9029 -- Source: Wos |
